SELLAS Announces U.S. FDA Rare Pediatric Disease Designation Granted to SLS009 for the Treatment of Pediatric Acute Lymphoblastic Leukemia

NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad...

Articles similaires

FDA Approves Ohtuvayre (ensifentrine) for the Maintenance Treatment of Chronic Obstructive Pulmonary Disease (COPD)

drugs.com - 26/Jun 21:06

LONDON and RALEIGH, N.C., June 26, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the...

Sellas Life Sciences receives IDMC recommendation to continue phase 3 REGAL trial in acute myeloid leukaemia

pharmabiz.com - 18/Jun 00:00

Sellas Life Sciences Group, Inc., a late─stage clinical biopharmaceutical company, announced a positive review of the ongoing phase 3 REGAL clinical...

MindMed to be Included in Russell 2000® and Russell 3000® Indexes

financialpost.com - 28/Jun 11:07

NEW YORK — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the “Company” or “MindMed”), a clinical stage biopharmaceutical...

Crohn’s Disease Pipeline Outlook 2024: FDA, EMA, PDMA Approvals, Therapies, Clinical Trials, Treatment Market, Mechanism of Action, ROA and Companies by DelveInsight

mountaintoday.in - 19/Jun 07:04

Crohn’s Disease Pipeline (New York, United States) As per DelveInsight’s assessment, globally, Crohn’s Disease pipeline constitutes 70+ key...

University of Nebraska Medical Center enrolls patient for RenovoRx's pivotal phase III TIGeR─PaC trial

pharmabiz.com - 28/Jun 00:00

RenovoRx, Inc, a clinical─stage biopharmaceutical company developing novel precision oncology therapies based on a local drug─delivery platform,...

Mozart Therapeutics Doses First Cohort of Participants in Phase 1a/b Clinical Trial of MTX-101, in Development for Treatment of Autoimmune Diseases

drugs.com - 17/Jun 22:06

SEATTLE, June 17, 2024. Mozart Therapeutics, a clinical stage biopharmaceutical company focused on the development of CD8 Treg modulators in...

Sirnaomics Announces Completion of STP707 Phase I Clinical Study with Strong Safety Profile and Disease Activity for the Treatment of Pancreatic Cancer Patients

drugs.com - 29/Jun 22:06

HONG KONG, GERMANTOWN, Md. and SUZHOU, China, June 28, 2024 Sirnaomics Ltd. (the "Company", together with its subsidiaries, the "Group" or...

Obesity Pipeline and Clinical Trials Assessment 2024: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Merck, Alizyme, Bayer, GlaxoSmithKline, Bristol-Myers Squibb, Currax Pharma

mountaintoday.in - 19/Jun 10:44

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Obesity pipeline constitutes 100+ key companies continuously working...

Synaptogenix gets US FDA authorization of IND application for clinical trial for Bryostatin─1 to treat multiple sclerosis

pharmabiz.com - 00:00

Synaptogenix, Inc., an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, announced that the Food & Drug...

Raya Therapeutic announces supportive clinical results of fasudil in amyotrophic lateral sclerosis patients

pharmabiz.com - 18/Jun 00:00

Raya Therapeutic Inc., (Raya) a mission─driven company focused on the treatment of ALS and other neurodegenerative diseases, announced supportive...

Les derniers communiqués

Adobe Brings Conversational AI to Trillions of PDFs with the New AI Assistant in Reader and Acrobat
Adobe - 21/02/2024
Laura Frigenti takes the Helm as Chief Executive Officer of the Global Partnership for Education
Global Partnership for Education - 05/12/2022

Rubriques :

Articles similaires

Les derniers communiqués